| 51 |
30933547 | An update on the safety of SGLT2 inhibitors. | 2019 Apr |
1 |
| 52 |
31041606 | Sodium-Glucose Co-Transporter 2 Inhibitors Compared with Sulfonylureas in Patients with Type 2 Diabetes Inadequately Controlled on Metformin: A Meta-Analysis of Randomized Controlled Trials. | 2019 Jun |
3 |
| 53 |
31120717 | Cost-effectiveness of DPP-4 inhibitor and SGLT2 inhibitor combination therapy for type 2 diabetes. | 2019 May |
1 |
| 54 |
31148423 | [GLP-1 analogues in 2019 : for whom and how ?] | 2019 May 29 |
1 |
| 55 |
31271575 | Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus with inadequate glycemic control on metformin: a meta-analysis. | 2019 |
1 |
| 56 |
31359366 | Treatment of Type 2 Diabetes by Patient Profile in the Clinical Practice of Endocrinology in Spain: Delphi Study Results from the Think Twice Program. | 2019 Oct |
1 |
| 57 |
31375850 | [Outcome studies on SGLT-2 inhibitors]. | 2019 Sep |
1 |
| 58 |
31410711 | What Next After Metformin? Thinking Beyond Glycaemia: Are SGLT2 Inhibitors the Answer? | 2019 Oct |
1 |
| 59 |
31440988 | Cardiorenal Protection: Potential of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes. | 2019 Oct |
1 |
| 60 |
31489272 | Sudden-onset Hypoglycemia Following Fluid Replacement in a Patient with Dapagliflozin-induced Diabetic Ketoacidosis Without Prior Insulin Use: Case Report. | 2019 Aug 21 |
1 |
| 61 |
31806203 | Cost Utility of Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Metformin Monotherapy Failed Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis. | 2019 Dec |
1 |
| 62 |
29375082 | Efficacy and safety of sodium-glucose cotransporter 2 inhibitors as add-on to metformin and sulfonylurea treatment for the management of type 2 diabetes: a meta-analysis. | 2018 Mar 28 |
1 |
| 63 |
29412124 | Sodium-glucose Cotransporter 2 Inhibitors: Glucose Lowering Against other Hypoglycemic Agents. | 2018 |
2 |
| 64 |
29516618 | Sodium-glucose co-transporter-2 inhibitors, the latest residents on the block: Impact on glycaemic control at a general practice level in England. | 2018 Jul |
3 |
| 65 |
29984503 | Making sense of newer treatment options for type 2 diabetes. | 2018 Jul |
1 |
| 66 |
30008267 | Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink. | 2018 Jul 16 |
2 |
| 67 |
30013414 | Combination of Empagliflozin and Metformin Therapy: A Consideration of its Place in Type 2 Diabetes Therapy. | 2018 |
2 |
| 68 |
30068236 | The safety of empagliflozin plus metformin for the treatment of type 2 diabetes. | 2018 Aug |
3 |
| 69 |
30219950 | Replacement Effects and Budget Impacts of Insurance Coverage for Sodium-Glucose Co-Transporter-2 Inhibitors on Oral Antidiabetic Drug Utilization. | 2018 Dec |
2 |
| 70 |
30509271 | Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus. | 2018 Dec 3 |
1 |
| 71 |
27995594 | Liraglutide Versus SGLT-2 Inhibitors in People with Type 2 Diabetes: A Network Meta-Analysis. | 2017 Feb |
1 |
| 72 |
28105986 | Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation. | 2017 Jan |
2 |
| 73 |
28152176 | Metformin-SGLT2, Dehydration, and Acidosis Potential. | 2017 May |
1 |
| 74 |
28276972 | Pharmacotherapy of 'treatment resistant' type 2 diabetes. | 2017 Apr |
1 |
| 75 |
28332871 | SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO. | 2017 Jul |
3 |
| 76 |
28542373 | Comparative effectiveness of oral antidiabetic drugs in preventing cardiovascular mortality and morbidity: A network meta-analysis. | 2017 |
2 |
| 77 |
28682870 | Long-term efficacy and safety of sodium-glucose cotransporter-2 inhibitors as add-on to metformin treatment in the management of type 2 diabetes mellitus: A meta-analysis. | 2017 Jul |
2 |
| 78 |
28797524 | Systematic review of metformin monotherapy and dual therapy with sodium glucose co-transporter 2 inhibitor (SGLT-2) in treatment of type 2 diabetes mellitus. | 2017 Oct |
4 |
| 79 |
29174215 | Choosing Dipeptidyl Peptidase-4 Inhibitors, Sodium-glucose Cotransporter-2 Inhibitors, or Both, as Add-ons to Metformin: Patient Baseline Characteristics Are Crucial. | 2017 Dec |
1 |
| 80 |
26854518 | Sodium-glucose cotransporter 2 inhibitors: an evidence-based practice approach to their use in the natural history of type 2 diabetes. | 2016 May |
1 |
| 81 |
26911584 | SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. | 2016 Feb 24 |
1 |
| 82 |
27042132 | Sodium-glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin-metformin. | 2016 |
2 |
| 83 |
27268470 | Cardiovascular effects of anti-diabetes drugs. | 2016 Sep |
1 |
| 84 |
27495291 | A post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures. | 2016 Aug 5 |
1 |
| 85 |
28760225 | Renal safety profile of sodium-glucose cotransporter-2 inhibitors and other safety data. | 2016 Nov |
1 |
| 86 |
25216510 | Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapy. | 2015 Mar |
1 |
| 87 |
25644093 | Empagliflozin added to metformin and sulfonylurea therapy in patients with sub-optimally controlled type 2 diabetes mellitus. | 2015 Apr |
1 |
| 88 |
25671589 | Selective reaction monitoring of negative electrospray ionization acetate adduct ions for the bioanalysis of dapagliflozin in clinical studies. | 2015 Mar 17 |
2 |
| 89 |
25812364 | [Biguanide]. | 2015 Mar |
1 |
| 90 |
24829965 | The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. | 2014 May |
1 |
| 91 |
25015317 | Combinational therapy with metformin and sodium-glucose cotransporter inhibitors in management of type 2 diabetes: systematic review and meta-analyses. | 2014 Sep |
2 |
| 92 |
25246775 | Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. | 2014 |
1 |
| 93 |
25554070 | Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence. | 2014 Dec |
1 |
| 94 |
24007456 | Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control. | 2013 Sep 5 |
1 |
| 95 |
19943222 | Dapagliflozin, an oral sodium glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus. | 2009 Dec |
1 |